[Expression of COX-2 in prostatic cancer and benign prostatic hyperplasia].
To investigate the expression of COX-2 in and benign prostatic hyperplasia and prostate cancer and its clinical implications. Forty-two patients with and benign prostatic hyperplasia and 16 with prostate cancer were studied by immunohischemistry and western blot. Immunohischemiscal study showed positive results in 15 of the 16 patients and 11 of the 42 patients. Western blot showed that the expression of COX-2 was higher in prostate cancer than in and benign prostatic hyperplasia tissues(P < 0.01). Overexpression of COX-2 in prostate cancer may be related to the staging of prostate cancer.